Regulatory considerations on endpoints in ovarian cancer drug development-Reference-Cited by-同舟云学术

Regulatory considerations on endpoints in ovarian cancer drug development

Published:2017-05-12 Issue:14 Volume:123 Page:2604-2608
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Balasubramaniam Sanjeeve¹,Kim Geoffrey S.¹,McKee Amy E.¹,Pazdur Richard¹

Affiliation:

1. Center for Drug Evaluation and Research; US Food and Drug Administration; Silver Spring Maryland

Funder

US federal government

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference15 articles.

1. Ovarian cancer outcomes: predictors of early death;Urban;Gynecol Oncol.,2016

2. Cancer statistics, 2016;Siegel;CA Cancer J Clin.,2016

3. US Food and Drug Administration June 25, 2014: Oncologic Drugs Advisory Committee Meeting Announcement http://www.fda.gov/AdvisoryCommittees/Calendar/ucm394126.htm 2016

4. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N Engl J Med.,2006

5. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference;Stuart;Int J Gynecol Cancer.,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cordyceps militarisExerts Antitumor Effect on Carboplatin-Resistant Ovarian Cancer via Activation of ATF3/TP53 Signaling In Vitro and In Vivo;Natural Product Communications;2020-01

2. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death;Scientific Reports;2018-12

3. The ADP-Ribosyl-Transferases Diphtheria Toxin-Like (ARTDs) Family: An Overview;Challenges;2018-05-27

4. Drug development and registration: Challenges and opportunities in ovarian cancer;Cancer;2017-05-12